Effects of dexlansoprazole: A Synthesis of Findings from 26 Studies

  1. Home
  2. Effects of dexlansoprazole
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of dexlansoprazole: A Synthesis of Findings from 26 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of dexlansoprazole: A Synthesis of Findings from 26 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Dexlansoprazole is a proton pump inhibitor (PPI) used to treat acid-related disorders. 22 found that PPIs, including dexlansoprazole, are affected by each patient's CYP2C19 and gastric H+,K+-ATPase genotype, influencing their pharmacokinetics and pharmacodynamics. 5 found that dexlansoprazole MR, a dual delayed-release formulation of a PPI, led to moderate increases in plasma gastrin levels in healthy subjects. 8 found that esomeprazole, another PPI, exhibited protective effects against cisplatin-induced ototoxicity. 19 found that dexlansoprazole caused morphological changes in the nematode C. elegans, suggesting potential off-target effects. 2 found that higher body mass index (BMI) is a risk factor for gastroesophageal reflux disease (GERD) and may affect the response to PPI therapy. 1 investigated the bioavailability of a dexlansoprazole delayed-release orally disintegrating tablet, examining the effects of food and mode of administration. 10 suggested that long-term use of PPIs, including dexlansoprazole, may increase the risk of gastric cancer. 13 discussed the clinical efficacy of PPIs initiated before endoscopy in patients with upper gastrointestinal bleeding. 21 found that PPIs enhance the antiviral activity of acyclovir against herpes simplex virus. 9 suggested that dexlansoprazole may have antiviral activity against SARS-CoV-2. 23 described the development of dexlansoprazole delayed-release capsules. 11 discussed the association between PPI use and bone health, particularly long-term use. 7 investigated the long-term efficacy of high-dose PPIs with cryotherapy for Barrett's esophagus. 12 evaluated the reported association between the syndrome of inappropriate antidiuretic hormone secretion (SIADH) and PPI use. 6 performed a network meta-analysis to compare the nocturnal acid-inhibitory effects of various acid-suppressive drugs. 20 compared the efficacy of reverse hybrid therapy and concomitant therapy for Helicobacter pylori infection. 18 compared the efficacy of clarithromycin triple therapy with or without N-acetylcysteine for Helicobacter pylori infection. 15 investigated the interaction between PPIs and clopidogrel. 16 compared the efficacy and safety of 7-day and 10-day levofloxacin-dexlansoprazole triple therapy for Helicobacter pylori infection. 24 evaluated the effect of dexlansoprazole and esomeprazole on bone homeostasis in healthy postmenopausal women. 25 evaluated the effect of six PPIs on the antiplatelet effects of clopidogrel. compared H2-receptor antagonists and PPIs for GERD and peptic ulcer disease. 14 investigated the association between PPI use and acute kidney injury and chronic kidney disease. 17 estimated the use of potentially inappropriate medications among older adults in the United States. provided comparison tables of H2-receptor antagonists and PPIs.

Benefits and Risks

Benefits Summary

Dexlansoprazole, a proton pump inhibitor (PPI), effectively reduces stomach acid production, potentially relieving symptoms such as heartburn and acid reflux. 23 found that a dual delayed-release formulation of dexlansoprazole showed extended duration of therapeutic plasma drug concentrations compared to a conventional lansoprazole formulation. 20 found that reverse hybrid therapy was non-inferior to concomitant therapy for first-line treatment of Helicobacter pylori infection. 18 suggested that adding N-acetylcysteine to clarithromycin triple therapy for Helicobacter pylori infection may improve its efficacy. 21 found that PPIs, including dexlansoprazole, can enhance the antiviral activity of acyclovir against herpes simplex virus, making them potential candidates for combination therapy. 8 suggests that esomeprazole, another PPI, may protect against cisplatin-induced ototoxicity. While dexlansoprazole, like other PPIs, is effective for many patients, potential side effects should be considered.

Risks Summary

Dexlansoprazole, like other PPIs, carries a risk of side effects. 14 found a potential association between PPI use and acute kidney injury and chronic kidney disease. 11 highlighted the potential association between long-term PPI use and osteoporotic fractures. 12 investigated the reported association between PPI use and the syndrome of inappropriate antidiuretic hormone secretion (SIADH). 17 estimated the use of potentially inappropriate medications among older adults in the United States. 22 highlighted the impact of CYP2C19 and gastric H+,K+-ATPase genotype on the pharmacokinetics and pharmacodynamics of PPIs. 5 found that dexlansoprazole can increase plasma gastrin levels. Long-term or high-dose use should be carefully considered, and dexlansoprazole, like many effective drugs, carries potential side effects.

Comparison of Studies

Commonalities of Studies

Many studies have consistently shown that dexlansoprazole is effective in reducing stomach acid production. 23 found that a dual delayed-release formulation of dexlansoprazole showed extended duration of therapeutic plasma drug concentrations compared to a conventional lansoprazole formulation. 20 found that reverse hybrid therapy was non-inferior to concomitant therapy for first-line treatment of Helicobacter pylori infection. 18 suggested that adding N-acetylcysteine to clarithromycin triple therapy for Helicobacter pylori infection may improve its efficacy. 21 found that PPIs, including dexlansoprazole, can enhance the antiviral activity of acyclovir against herpes simplex virus, making them potential candidates for combination therapy. 8 suggests that esomeprazole, another PPI, may protect against cisplatin-induced ototoxicity.

Differences in Studies

Different studies have yielded varying results regarding the effects and safety of dexlansoprazole. 14 found a potential association between PPI use and acute kidney injury and chronic kidney disease. 11 highlighted the potential association between long-term PPI use and osteoporotic fractures. 12 investigated the reported association between PPI use and the syndrome of inappropriate antidiuretic hormone secretion (SIADH). 17 estimated the use of potentially inappropriate medications among older adults in the United States. 22 highlighted the impact of CYP2C19 and gastric H+,K+-ATPase genotype on the pharmacokinetics and pharmacodynamics of PPIs. 5 found that dexlansoprazole can increase plasma gastrin levels.

Consistency and Discrepancies in Findings

There are discrepancies in findings regarding the effects and safety of dexlansoprazole. 14 found a potential association between PPI use and acute kidney injury and chronic kidney disease. 11 highlighted the potential association between long-term PPI use and osteoporotic fractures. 12 investigated the reported association between PPI use and the syndrome of inappropriate antidiuretic hormone secretion (SIADH). 17 estimated the use of potentially inappropriate medications among older adults in the United States. 22 highlighted the impact of CYP2C19 and gastric H+,K+-ATPase genotype on the pharmacokinetics and pharmacodynamics of PPIs. 5 found that dexlansoprazole can increase plasma gastrin levels. Further research is needed to draw definitive conclusions about the long-term effects and potential risks.

Considerations for Real-World Applications

Dexlansoprazole is effective in reducing stomach acid and can alleviate symptoms like heartburn and acid reflux. 23 found that a dual delayed-release formulation of dexlansoprazole showed extended duration of therapeutic plasma drug concentrations compared to a conventional lansoprazole formulation. 20 found that reverse hybrid therapy was non-inferior to concomitant therapy for first-line treatment of Helicobacter pylori infection. 18 suggested that adding N-acetylcysteine to clarithromycin triple therapy for Helicobacter pylori infection may improve its efficacy. 21 found that PPIs, including dexlansoprazole, can enhance the antiviral activity of acyclovir against herpes simplex virus, making them potential candidates for combination therapy. 8 suggests that esomeprazole, another PPI, may protect against cisplatin-induced ototoxicity. However, it's essential to remember that, like other PPIs, dexlansoprazole carries a risk of side effects. 14 found a potential association between PPI use and acute kidney injury and chronic kidney disease. 11 highlighted the potential association between long-term PPI use and osteoporotic fractures. 12 investigated the reported association between PPI use and the syndrome of inappropriate antidiuretic hormone secretion (SIADH). 17 estimated the use of potentially inappropriate medications among older adults in the United States. 22 highlighted the impact of CYP2C19 and gastric H+,K+-ATPase genotype on the pharmacokinetics and pharmacodynamics of PPIs. 5 found that dexlansoprazole can increase plasma gastrin levels. Dexlansoprazole should only be used as directed by a healthcare professional.

Limitations of Current Research

There are gaps in our understanding of the long-term effects and safety of dexlansoprazole. 14 found a potential association between PPI use and acute kidney injury and chronic kidney disease. 11 highlighted the potential association between long-term PPI use and osteoporotic fractures. 12 investigated the reported association between PPI use and the syndrome of inappropriate antidiuretic hormone secretion (SIADH). 17 estimated the use of potentially inappropriate medications among older adults in the United States. 22 highlighted the impact of CYP2C19 and gastric H+,K+-ATPase genotype on the pharmacokinetics and pharmacodynamics of PPIs. 5 found that dexlansoprazole can increase plasma gastrin levels. More research is needed to address these limitations.

Future Research Directions

Further investigation is needed to better understand the effects and safety of dexlansoprazole, particularly its long-term impacts and potential risks. 14 found a potential association between PPI use and acute kidney injury and chronic kidney disease. 11 highlighted the potential association between long-term PPI use and osteoporotic fractures. 12 investigated the reported association between PPI use and the syndrome of inappropriate antidiuretic hormone secretion (SIADH). 17 estimated the use of potentially inappropriate medications among older adults in the United States. 22 highlighted the impact of CYP2C19 and gastric H+,K+-ATPase genotype on the pharmacokinetics and pharmacodynamics of PPIs. 5 found that dexlansoprazole can increase plasma gastrin levels. More extensive and long-term studies are crucial to address the concerns raised by previous research.

Conclusion

Dexlansoprazole is a PPI that effectively reduces stomach acid, offering relief from symptoms such as heartburn and acid reflux. 23 found that a dual delayed-release formulation of dexlansoprazole showed extended duration of therapeutic plasma drug concentrations compared to a conventional lansoprazole formulation. 20 found that reverse hybrid therapy was non-inferior to concomitant therapy for first-line treatment of Helicobacter pylori infection. 18 suggested that adding N-acetylcysteine to clarithromycin triple therapy for Helicobacter pylori infection may improve its efficacy. 21 found that PPIs, including dexlansoprazole, can enhance the antiviral activity of acyclovir against herpes simplex virus, making them potential candidates for combination therapy. 8 suggests that esomeprazole, another PPI, may protect against cisplatin-induced ototoxicity. However, it is essential to be aware of potential side effects and to use dexlansoprazole only as directed by a healthcare professional. 14 found a potential association between PPI use and acute kidney injury and chronic kidney disease. 11 highlighted the potential association between long-term PPI use and osteoporotic fractures. 12 investigated the reported association between PPI use and the syndrome of inappropriate antidiuretic hormone secretion (SIADH). 17 estimated the use of potentially inappropriate medications among older adults in the United States. 22 highlighted the impact of CYP2C19 and gastric H+,K+-ATPase genotype on the pharmacokinetics and pharmacodynamics of PPIs. 5 found that dexlansoprazole can increase plasma gastrin levels. Further research is needed to fully understand the long-term implications and potential risks associated with dexlansoprazole.

Literature analysis of 26 papers
Positive Content
20
Neutral Content
3
Negative Content
3
Article Type
8
0
1
4
26
2.

The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.

Author: PeuraD A, PilmerB, HuntB, ModyR, PerezM C

Reduced heartburn symptoms

Proton pump inhibitors reduced heartburn symptoms regardless of baseline body mass index (BMI) in patients with non-erosive GERD or erosive oesophagitis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.

Author: FrelingerAndrew L, LeeRonald D, MulfordDarcy J, WuJingtao, NudurupatiSai, NigamAnu, BrooksJulie K, BhattDeepak L, MichelsonAlan D

Reduced clopidogrel efficacy

Generation of clopidogrel active metabolite and inhibition of platelet function were reduced less by the coadministration of dexlansoprazole or lansoprazole with clopidogrel than by the coadministration of esomeprazole or omeprazole. These results suggest that the potential of PPIs to attenuate the efficacy of clopidogrel could be minimized by the use of dexlansoprazole or lansoprazole rather than esomeprazole or omeprazole.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease.

Author: FassR, CheyW D, ZakkoS F, AndhivarothaiN, PalmerR N, PerezM C, AtkinsonS N

Non-erosive reflux disease treatment
Reduced heartburn
Adverse events

Dexlansoprazole MR 30 and 60 mg were superior to placebo in providing 24-h heartburn-free days and nights in non-erosive reflux disease (NERD) patients. The treatment was well tolerated.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

5.

Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects.

Author: ZhangWeijiang, WuJingtao, AtkinsonStuart N

Acid-related disorder treatment
Gastrin increase

This study found that dexlansoprazole MR, a modified release formulation of a proton pump inhibitor, caused moderate increases in plasma gastrin levels similar to lansoprazole, which returned to baseline within 7 days of stopping the medication.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

8.

Protective effects of esomeprazole against cisplatin-induced ototoxicity: an in vitro and in vivo study.

Author: JeonHanul, SongIn Sik, ParkJin-Gyeong, LeeHyejin, HanEunjung, ParkSaemi, LeeYunkyoung, SongChi-Man, HurWooyoung, LeeIn-Gyun, ChoiJune

Ototoxicity prevention
Cisplatin-induced ototoxicity

Esomeprazole showed a protective effect against cisplatin-induced hair cell damage in both HEI-OC1 cells and a zebrafish model. Esomeprazole inhibited organic cation transporter 2 (OCT2), providing in vitro evidence that it could ameliorate cisplatin-induced ototoxicity.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

9.

Evaluation of In Vitro and In Vivo Antiviral Activities of Vitamin D for SARS-CoV-2 and Variants.

Author: MokChee-Keng, NgYan Ling, AhidjoBintou Ahmadou, AwZhen Qin, ChenHuixin, WongYi Hao, LeeRegina Ching Hua, LoeMarcus Wing Choy, LiuJing, TanKai Sen, KaurParveen, WangDe Yun, HaoErwei, HouXiaotao, TanYong Wah, DengJiagang, ChuJustin Jang Hann

Treats COVID-19

A drug screen identified several promising anti-SARS-CoV-2 compounds, with calcitriol (active vitamin D) showing strong potency in cell-based assays. Calcitriol's antiviral effect is associated with increased antimicrobial peptide expression through modulation of the vitamin D receptor pathway.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

10.

Suppression of vacuolar-type ATPase and induction of endoplasmic reticulum stress by proton pump inhibitors.

Author: LeeWei-Ping

Acid-related disorders treatment
Gastric cancer

Proton pump inhibitors (PPIs) are commonly used medications, but long-term use has been linked to an increased risk of gastric cancer. This study aims to investigate the underlying mechanism of PPI-mediated gastric cancer.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

11.

Proton Pump Inhibitors and Bone Health: An Update Narrative Review.

Author: LespessaillesEric, ToumiHechmi

Acid-related disorders treatment
Osteoporotic fracture

This narrative review discusses the recent findings pertaining to the risk of osteoporotic fracture associated with proton pump inhibitors (PPIs). The evidence suggests a potential link between long-term PPI use and fracture risk, but further research is needed to elucidate the mechanisms involved.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

13.

Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding.

Author: KannoTakeshi, YuanYuhong, TseFrances, HowdenColin W, MoayyediPaul, LeontiadisGrigorios I

PPIs for upper GI bleeding
Conflicting evidence

This study reviews the evidence regarding the clinical efficacy of proton pump inhibitors (PPIs) for managing upper gastrointestinal (GI) bleeding. PPIs reduce gastric acid production and are commonly used for upper GI bleeding, but their effectiveness before endoscopy remains unclear.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

16.

Efficacy and safety of 7 days versus 10 days triple therapy based on levofloxacin-dexlansoprazole for eradication of <i>Helicobacter pylori</i>: A pilot randomized trial.

Author: ElkhodaryNoha Mahmoud, FarragKhaled Abdalkader, ElokabyAmany Mahmoud, El-Hay OmranGamal Abd

H. pylori eradication

This study examines the efficacy of levofloxacin-based triple therapies for the eradication of Helicobacter pylori (H. pylori) and the optimal duration of treatment. It also investigates the efficacy of dexlansoprazole in H. pylori eradication.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

17.

Estimating the Use of Potentially Inappropriate Medications Among Older Adults in the United States.

Author: FralickMichael, BartschEmily, RitchieChristine S, SacksChana A

Medication errors

This study aims to estimate the extent and cost of potentially inappropriate prescribing of medications to older adults in the United States, a significant safety concern due to their high burden of comorbidity and risk for medication-related adverse events.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

18.

Comparison of the effect of clarithromycin triple therapy with or without <i>N</i>-acetylcysteine in the eradication of <i>Helicobacter pylori</i>: a randomized controlled trial.

Author: ChenChieh-Chang, LuoJiing-Chyuan, FangYu-Jen, LeeJi-Yuh, KuoChia-Chi, YangTsung-Hua, ChiuMin-Chin, YuJian-Jyun, BairMing-Jong, ChenPo-Yueh, ChouChu-Kuang, ChenChi-Yi, ChangChi-Yang, HsuYao-Chun, TsengCheng-Hao, HsuWen-Feng, HuWen-Hao, TsaiMin-Horn, HsiehCheng-Lin, ChenMei-Jyh, ShunChia-Tung, LiuTzeng-Ying, LeeYi-Chia, LiouJyh-Ming, WuMing-Shiang,

H. pylori treatment

This study aimed to compare the efficacy of 14-day triple therapy with or without N-acetylcysteine (NAC) for the first-line treatment of Helicobacter pylori infection.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

20.

Equivalent efficacies of reverse hybrid and concomitant therapies in first-line treatment of Helicobacter pylori infection.

Author: HsuPing-I, TsayFeng-Woei, KaoJohn Y, PengNan-Jing, TsaiKuo-Wang, TsaiTzung-Jiun, KuoChao-Hung, KaoSung-Shuo, WangHuay-Min, ChenYan-Hua, ShieChang-Bih, WuDeng-Chyang,

Effective treatment for H. pylori

This study aims to test whether 14-day reverse hybrid therapy is non-inferior to 14-day concomitant therapy in the first-line treatment of Helicobacter pylori infection.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

21.

Omeprazole Increases the Efficacy of Acyclovir Against Herpes Simplex Virus Type 1 and 2.

Author: MichaelisMartin, KleinschmidtMalte C, BojkovaDenisa, RabenauHolger F, WassMark N, CinatlJindrich

Antiviral therapy

This study investigated the effects of omeprazole on the antiviral activity of ribavirin and acyclovir. Omeprazole enhanced the antiviral effects of acyclovir against herpes simplex virus 1 and 2 (HSV-1 and -2), suggesting its potential use in combination antiviral therapies.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

22.

Effects of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of proton pump inhibitors.

Author: ZhangHe-Jian, ZhangXue-Hui, LiuJie, SunLu-Ning, ShenYi-Wen, ZhouChen, ZhangHong-Wen, XieLi-Jun, ChenJuan, LiuYun, WangYong-Qing

Acid-related disorder treatment

This review analyzed the effect of genetic polymorphisms on the pharmacodynamic and pharmacokinetic properties of proton pump inhibitors (PPIs).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

23.

Development of Dexlansoprazole Delayed-Release Capsules, a Dual Delayed-Release Proton Pump Inhibitor.

Author: GradyHaiyan, MurakawaYusuke, MulfordDarcy, KukulkaMichael

Acid-related disorder treatment
Extended duration of action

Dexplansoprazole is a proton pump inhibitor (PPI) used to treat heartburn and acid reflux. It is a more advanced version of lansoprazole that is absorbed more quickly and stays in the body longer.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

24.

Dexlansoprazole and Esomeprazole Do Not Affect Bone Homeostasis in Healthy Postmenopausal Women.

Author: HansenKaren E, NievesJeri W, NudurupatiSai, MetzDavid C, PerezMaria Claudia

Osteoporosis

This study evaluated the effect of dexlansoprazole and esomeprazole on bone turnover, bone mineral density (BMD), true fractional calcium absorption (TFCA), serum and urine levels of minerals, and levels of parathyroid hormone (PTH) in healthy postmenopausal women. The results showed that dexlansoprazole and esomeprazole had no significant effect on bone turnover, BMD, TFCA, or mineral levels.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

25.

Evaluating the Effect of Six Proton Pump Inhibitors on the Antiplatelet Effects of Clopidogrel.

Author: PrzespolewskiEugene R, WestphalErica S, RainkaMichelle, SmithNicholas M, BatesVernice, GengoFran M

Antiplatelet effects
Compromised clopidogrel effects

This study investigated the potential interaction between clopidogrel and proton pump inhibitors (PPIs), particularly esomeprazole and omeprazole. While previous studies have raised concerns about PPIs compromising clopidogrel's antiplatelet effects, this study suggests that the interaction may not be as robust as previously thought, calling for further investigation to assess the clinical relevance of this interaction.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

26.

First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease.

Author: LiangChih-Ming, KuoMing-Te, HsuPin-I, KuoChao-Hung, TaiWei-Chen, YangShih-Cheng, WuKeng-Liang, WangHsing-Ming, YaoChih-Chien, TsaiCheng-En, WangYao-Kuang, WangJiunn-Wei, HuangChih-Fang, WuDeng-Chyang, ChuahSeng-Kee,

GERD treatment

The study found that the overall CSR for GERD patients was similar at days 1-7 for both the dexlansoprazole and esomeprazole groups, although a higher incidence of CSR was observed on day 3 in female patients who received a single dose of dexlansoprazole.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.